Breaking News
Romanian Man Is Sentenced in 2023 Wave of ‘Swatting’ Calls « Pacte national : Himler Rébu évoque des signataires ayant “consommé trop de clairin de Léogâne” » France steps up vaccination push as anti-vax fears grow in Europe Chick-fil-A Bilked for $80,000 in Fake Mac-and-Cheese Refunds, Police Say Here’s What States Might Do After the Voting Rights Decision Pour saluer la mémoire de Michèle Voltaire Marcelin, poétesse, peintre, romancière et comédienne Senator Reed, a Democrat, attacks Hegseth right out of the gate. How A.I. Killed Student Writing (and Revived It) French unions rally on Labour Day to defend paid holiday rights Takeaways From Hegseth’s Second Day of Testimony on the Iran War Romanian Man Is Sentenced in 2023 Wave of ‘Swatting’ Calls « Pacte national : Himler Rébu évoque des signataires ayant “consommé trop de clairin de Léogâne” » France steps up vaccination push as anti-vax fears grow in Europe Chick-fil-A Bilked for $80,000 in Fake Mac-and-Cheese Refunds, Police Say Here’s What States Might Do After the Voting Rights Decision Pour saluer la mémoire de Michèle Voltaire Marcelin, poétesse, peintre, romancière et comédienne Senator Reed, a Democrat, attacks Hegseth right out of the gate. How A.I. Killed Student Writing (and Revived It) French unions rally on Labour Day to defend paid holiday rights Takeaways From Hegseth’s Second Day of Testimony on the Iran War
Live Updates: Haitian Business Spotlight Politics Entertainment Sports Business Haiti News U.S. News Canada News
France News

Biogaran sale talks renew fears over foreign control of French pharma

Haitian Globe
Author
August 4, 2025
Published
1 min read
Reading time
54
Views
Share:
Embed on your website
Biogaran sale talks renew fears over foreign control of French pharma

France’s top generic drug maker, Biogaran, could soon be sold to a British investment fund, raising new fears about the country’s control over vital medicines.

Advertisement

About the Author

Haitian Globe

Site administrator for Haitian Globe

Sponsored

Comments (0)

Add a Comment

No comments yet